AtCor wins $1.1m deal for SphygmoCor XCEL
Wednesday, 15 August, 2012
AtCor Medical (ASX:ACG) has secured a $1.1 million contract to provide its SphygmoCor XCEL cardiac monitoring system to an international pharmaceutical company.
The deal covers the supply of SphygmoCor XCEL systems as well as clinical trial support services. The pharmaceutical company in question has not been named.
SphyhmoCor XCEL is the improved version of AtCor's SphygmoCor central aortic blood pressure and arterial stiffness monitoring system.
The upgraded system automates and improves the process of data capturing, and can allow simultaneous brachial and central aortic blood pressure measurement. SphygmoCor XCEL was launched in May, in Australia, Europe and some Asian markets, and AtCor filed for FDA approval for the system late last month.
SphygmoCor is used by clinicians as a cardiac disease risk assessment tool, as well as in medical research and clinical trials. Around 2,700 systems are in use worldwide.
AtCor was founded in Sydney in 1994, and went public via a $15 million IPO in 2005. The company also has operations in the US and Europe.
AtCor Medical (ASX:ACG) shares were trading unchanged at $0.060 as of around 3pm on Tuesday.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
